UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, include area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On March 8, 2021, John Walker, Chairman of the Board of Directors (the “Board”) of Zosano Pharma Corporation (the “Company”), delivered notice of his intention to retire from the Board effective as of, and not stand for reelection at, the upcoming annual meeting of shareholders, which is currently scheduled for June 10, 2021. The Company expects that Mr. Walker will continue to serve in a consulting role to the Company following his retirement from the Board. Mr. Walker is retiring from the Board and his decision not to stand for reelection is not a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Forward-Looking Statements
This report contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Mr. Walker’s retirement from the Board or his continued service as a consultant to the Company. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. The Company does not plan to publicly update or revise any forward-looking statements contained in this report, whether as a result of any new information, future events, changed circumstances or otherwise.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 11, 2021 | ZOSANO PHARMA CORPORATION | |||||||
| By: | /s/ Christine Matthews |
|||||||
| Christine Matthews | ||||||||
| Chief Financial Officer | ||||||||
Document and Entity Information |
Mar. 08, 2021 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | Zosano Pharma Corp |
| Amendment Flag | false |
| Entity Central Index Key | 0001587221 |
| Document Type | 8-K |
| Document Period End Date | Mar. 08, 2021 |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-36570 |
| Entity Tax Identification Number | 45-4488360 |
| Entity Address, Address Line One | 34790 Ardentech Court |
| Entity Address, City or Town | Fremont |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94555 |
| City Area Code | (510) |
| Local Phone Number | 745-1200 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.0001 par value |
| Trading Symbol | ZSAN |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |